Münstedt K, Vahrson H
Department of Gynaecologic Oncology and Radiotherapy, Justus-Liebig-University Giessen, Germany.
Eur J Gynaecol Oncol. 1995;16(3):174-80.
The role of irradiation seems to be not very important in the post-operative treatment of cancer of the ovaries compared to chemotherapy although it has proved to be highly effective.
In a retrospective study 37 patients with advanced cancer of the ovaries Stages IIIb and IIIc (FIGO) undergoing post-operative consecutive radio-chemotherapy consisting of two series of whole abdominal radiation (WAR) applied in sandwich technique with 6 courses of cisplatin-epirubicin-cyclophosphamide (PEC) were evaluated. For the effectiveness of WAR and PEC-chemotherapy changes of CA 125 serum levels were noted.
Both WAR and PEC-chemotherapy proved to be effective in 50.5% of the patients, either WAR and PEC-chemotherapy were effective in 16.2% neither one affected the course of disease in 8.1%. Statistical analysis shows a good correlation between the effectiveness of WAR and survival but no such correlation as to the effectiveness of PEC-chemotherapy.
The role of irradiation in the treatment of ovarian cancer is underestimated. The addition of WAR at the beginning of the post-operative treatment can prolong the survival time in advanced stages of ovarian cancer.
与化疗相比,放疗在卵巢癌术后治疗中的作用似乎不是很重要,尽管已证明放疗非常有效。
在一项回顾性研究中,对37例FIGO分期为IIIb和IIIc期的晚期卵巢癌患者进行了评估,这些患者术后接受了连续放化疗,采用三明治技术进行两系列全腹放疗(WAR),并联合6个疗程的顺铂-表柔比星-环磷酰胺(PEC)化疗。记录CA 125血清水平的变化以评估WAR和PEC化疗的疗效。
WAR和PEC化疗在50.5%的患者中被证明有效,WAR和PEC化疗均有效的患者占16.2%,两者均未影响疾病进程的患者占8.1%。统计分析表明,WAR的疗效与生存率之间存在良好的相关性,但与PEC化疗的疗效不存在这种相关性。
放疗在卵巢癌治疗中的作用被低估了。术后治疗开始时加用WAR可延长晚期卵巢癌患者的生存时间。